Meeting
2022 ASCO Annual Meeting
A phase II study of stereotactic body radiotherapy (SBRT) combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma (HCC).
Authors
Yixing Chen
Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
Yixing Chen , Ping Yang , Shisuo Du , Jian Zhou , Cheng Huang , Wenchao Zhu , Yong Hu , Yiyi Yu , Tianshu Liu , Zhaochong Zeng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT03857815
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4071)
DOI
10.1200/JCO.2022.40.16_suppl.4071
Abstract #
4071
Poster Bd #
59
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Stereotactic body radiotherapy (SBRT) in difficult-to-treat areas (para-aortic lymphadenoapthy and pelvic recurrence) in oligometastatic colorectal carcinoma.
First Author: Indrani Subarna Bhattacharya
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Comparing resection and stereotactic body radiation therapy for hepatocellular carcinoma with macrovascular invasion: A propensity score matched study.
First Author: Michael Yan
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Fruquintinib combined with sintilimab plus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma: A single-arm phase II study.
First Author: Guoliang Shao
Poster
2023 ASCO Annual Meeting
Overall survival and subsequent therapy from a phase II study of sintilimab and anlotinib in patients with advanced or recurrent endometrial cancer.
First Author: Zhen Zeng